SNS COLLEGE OF TECHNOLOGY
(An Autonomous Institution)
Approved by AICTE, New Delhi, Affiliated to Anna University, Chennai
Accredited by NAAC-UGC with 'A++' Grade (Cycle III) &
Accredited by NBA (B.E - CSE, EEE, ECE, Mech & B.Tech.IT)
COIMBATORE-641 035, TAMIL NADU

UNIT V

STEM CELL AND TISSUE ENGINEERING

Stem Cells: Undifferentiated cells with the ability to self-renew and differentiate into specialized cell types.

Tissue Engineering: An interdisciplinary field combining biology, engineering, and materials science to restore, replace, or regenerate damaged tissues and organs.

Stem Cells

Types of Stem Cells

1. **Embryonic Stem Cells (ESCs)**:
    1. Derived from the inner cell mass of a blastocyst.
    2. **Pluripotent**: Can differentiate into any cell type in the body.
2. **Adult Stem Cells (ASCs)**:
    1. Found in specific tissues (e.g., bone marrow, skin).
    2. **Multipotent**: Can differentiate into a limited range of cell types (e.g., hematopoietic stem cells for blood cells).
3. **Induced Pluripotent Stem Cells (iPSCs)**:
    1. Somatic cells reprogrammed to behave like ESCs.
    2. Generated using transcription factors (e.g., Oct4, Sox2).
4. **Perinatal Stem Cells**:
    1. Found in the amniotic fluid or umbilical cord blood.
    2. Intermediate between embryonic and adult stem cells.

2.2 Applications of Stem Cells

1. **Regenerative Medicine**:
    1. Replacement of damaged tissues (e.g., spinal cord injuries, diabetes, heart disease).
2. **Drug Testing and Development**:
    1. Testing drugs on cell models derived from stem cells.
3. **Disease Modeling**:
    1. Using iPSCs to study genetic diseases (e.g., ALS, Parkinson's).
4. **Gene Therapy**:
    1. Correcting genetic defects using stem cells as delivery vehicles.

2.3 Challenges

- Ethical issues (especially for ESCs).
- Immune rejection and tumorigenesis risks.
- High cost and technical complexity.

3. Tissue Engineering

3.1 Principles

1. **Cells**:
   1. Autologous (patient-derived), allogeneic (donor-derived), or stem cells.
2. **Scaffolds**:
   1. Biocompatible structures that provide support for cell attachment and tissue growth.
   2. Made of natural (e.g., collagen, alginate) or synthetic (e.g., PLGA, PEG) materials.
3. **Bioactive Molecules**:
   1. Growth factors and signaling molecules to promote cell differentiation and proliferation.
4. **Bioreactors**:
   1. Devices providing controlled environments (temperature, oxygen, mechanical stimulation) for tissue culture.

3.2 Applications

1. **Organ Regeneration**:
   1. Engineering organs like skin, liver, kidneys, and lungs.
   2. Example: Lab-grown bladders and artificial tracheas.
2. **Wound Healing**:
   1. Skin substitutes for burn victims (e.g., *Integra*).
3. **Bone and Cartilage Repair**:
   1. Scaffolds seeded with stem cells for orthopedic applications.
4. **Vascular Tissue Engineering**:
   1. Creating blood vessels for bypass surgery or artificial organs.
5. **Disease Models**:
   1. Engineered tissues to study diseases and test therapies.

3.3 Challenges

- Difficulty in replicating complex tissue structures (e.g., vascularization).
- Immune response to scaffolds and cells.
- High cost and scalability issues for clinical use.

4. Integration of Stem Cells and Tissue Engineering

- Stem cells are increasingly used in tissue engineering due to their ability to differentiate into desired cell types.
- **Example**:
  - Engineering cardiac patches with stem cells to repair damaged heart tissue.
  - Using iPSCs to generate functional liver tissue.

5. Ethical and Regulatory Considerations

1. **Ethical Issues**:
   1. Controversy surrounding embryonic stem cell use.
   2. Access and equity in stem cell therapies.

2. **Regulatory Approvals**:
    1. Strict guidelines for clinical trials and use of engineered tissues.
    2. Oversight by bodies like the FDA or EMA.

Stem cell research and tissue engineering hold immense potential for revolutionizing medicine by providing solutions for organ shortages, regenerative therapies, and disease modeling. Addressing technical, ethical, and regulatory challenges will be key to translating these technologies into widespread clinical use.